Home / Health / Semaglutide Aids Non-Obese MASH Patients
Semaglutide Aids Non-Obese MASH Patients
9 Nov
Summary
- Semaglutide improved liver health markers in MASH patients below 27 BMI.
- Non-invasive fibrosis biomarkers also showed improvement with semaglutide.
- Study highlights MASH treatment for a potentially overlooked patient group.
Results from a post hoc analysis of the phase 3 ESSENCE trial indicate that once-weekly semaglutide 2.4 mg injection improved multiple liver health measures in adults with MASH and liver scarring who have a BMI below 27 kg/m². These improvements were observed at week 72 compared to placebo.
The analysis, presented at The Liver Meeting® 2026, also showed favorable results for non-invasive fibrosis biomarkers, such as ELF and PRO-C3, with semaglutide treatment. This data supplements existing histologic findings and emphasizes that MASH can affect individuals of all body types.
Semaglutide 2.4 mg is approved for adults with MASH and moderate-to-advanced liver scarring. The ESSENCE trial is evaluating its effect over 240 weeks. MASH is a serious liver disease affecting millions globally.
